Forget Zepbound: 3 Newer drugs that could power Eli Lilly's next leg higher The Motley Fool 6d The Motley Fool 6d Mounjaro Pharma All sources
Lilly’s Foundayo wins EMA panel backing for obesity and type 2 diabetes Pharmaceutical Technology 7d Pharmaceutical Technology 7d European Medicines Agency Obesity Diabetes All sources
Forget Eli Lilly and Novo: This biotech could be a surprising winner in the weight loss market The Motley Fool 4d The Motley Fool 4d Pharma Biotechnology Regeneron
Bristol Myers Squibb vs. Eli Lilly: How long can Zepbound and Mounjaro keep juicing Revenue results? The Motley Fool 20h The Motley Fool 20h Bristol Myers Squibb Mounjaro Pharma
Lilly’s Omvoh leads to 50% clinical remission rate in paediatric UC Clinical Trials Arena 4d Clinical Trials Arena 4d Omvoh Inflammatory Bowel Disease Pharma All sources
S&P 500 ends higher as traders shift from AI to healthcare Hong Kong Standard 7d Hong Kong Standard 7d UnitedHealth Group S&P 500 Stock Market (US) All sources
Eli Lilly breaks ground on $5 billion Goochland manufacturing facility 12 On Your Side 23:49 Thu, 22 Oct
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make Lly Stock a Better Buy in 2026? The Motley Fool 23:02 Thu, 22 Oct
Eli Lilly breaks ground on $5 billion production plant in Goochland Roanoke Times, Virginia 22:36 Thu, 22 Oct
Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020 PR Newswire (Press Release) 16:04 Thu, 22 Oct
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results? The Motley Fool 12:21 Thu, 22 Oct
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know Zacks 15:06 Wed, 21 Oct